TRI-JORDYNA 21 0.035 MG
ETHINYL ESTRADIOL : 0.035 MG NORGESTIMATE : 0.18 MG ETHINYL ESTRADIOL : 0.035 MG ETHINYL ESTRADIOL : 0.035 MG NORGESTIMATE : 0.215 MG NORGESTIMATE : 0.25 MG · DIN 02486296 · GLENMARK PHARMACEUTICALS CANADA INC.
Health Canada status: MARKETED
What is TRI-JORDYNA 21?
TRI-JORDYNA 21 0.035 MG contains ETHINYL ESTRADIOL : 0.035 MG NORGESTIMATE : 0.18 MG ETHINYL ESTRADIOL : 0.035 MG ETHINYL ESTRADIOL : 0.035 MG NORGESTIMATE : 0.215 MG NORGESTIMATE : 0.25 MG. It is listed in the Health Canada Drug Product Database under DIN 02486296, held by GLENMARK PHARMACEUTICALS CANADA INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 08-Jul-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02486296 |
|---|---|
| Brand name | TRI-JORDYNA 21 |
| Generic / active ingredient | ETHINYL ESTRADIOL : 0.035 MG NORGESTIMATE : 0.18 MG ETHINYL ESTRADIOL : 0.035 MG ETHINYL ESTRADIOL : 0.035 MG NORGESTIMATE : 0.215 MG NORGESTIMATE : 0.25 MG |
| Manufacturer | GLENMARK PHARMACEUTICALS CANADA INC. |
| Strength | 0.035 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G03AB09 NORGESTIMATE AND ETHINYLESTRADIOL |
| AHFS class | 68:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 08-Jul-2020 |
| Original market date | 2020-07-08 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code G03AB09 NORGESTIMATE AND ETHINYLESTRADIOL. 6 of 6 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| TRI-CIRA 21 | 0.035 MG | TABLET | APOTEX INC | MARKETED | DIN 02508087 |
| TRI-CIRA 28 | 0.215 MG | TABLET | APOTEX INC | MARKETED | DIN 02508095 |
| TRI-CIRA LO 21 | 0.025 MG | TABLET | APOTEX INC | MARKETED | DIN 02401967 |
| TRI-CIRA LO 28 | 0.025 MG | TABLET | APOTEX INC | MARKETED | DIN 02401975 |
| TRI-JORDYNA 28 | 0.25 MG | TABLET | GLENMARK PHARMACEUTICALS CANADA INC. | MARKETED | DIN 02486318 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.